Instil Bio provides SYN-2510 program overview in investor presentation

Instil Bio, Inc.

Company furnished presentation detailing its SYN-2510 program as of August 2024.
No specific clinical data, milestones, or financial projections disclosed in the filing.
The program overview does not include any changes to previously disclosed guidance or plans.

item 7.01 item 9.01

Instil Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001789769-24-000090

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.